Open AccessA review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
Author(s) -
Shim Hang Hock,
Chan Pak Wo,
Chuah Sai Wei,
Schwender Brian J,
Kong San Choon,
Ling Khoon Lin
Publication year - 2018
Publication title -
jgh open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 8
ISSN - 2397-9070
DOI - 10.1002/jgh3.12065
Subject(s) - vedolizumab , ustekinumab , medicine , inflammatory bowel disease , intensive care medicine , tumor necrosis factor alpha , randomized controlled trial , disease , infliximab
Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much‐awaited out‐of‐class alternatives for patients who have failed or who are intolerant to anti‐Tumor Necrosis Factor (TNF) therapy. However, questions remain as to how we may best use these novel therapeutic agents. We evaluate the evidence available from randomized controlled trials and postmarketing cohort studies and discuss their safety, efficacy, and limitations, in relation to anti‐TNF therapy, in optimizing the treatment outcomes.